Orexo AB Orexo AB

Orexo AB

ORX

Rank in Stocks #31173
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Share Price
$0.09638049
Last synced: 2026-11-20
Market Cap
$3.39M
Change (1 day)
-1.97%
Change (1 year)
-96.53%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Orexo AB (ORX)
Operating Margin as of November 2026 TTM: -2,860.32%
According to Orexo AB's latest financial reports, its current operating margin (TTM) is -2,860.32%. At the end of 2025 the company had an operating margin of -1,334.23%.
Operating Margin history for Orexo AB from 2002 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -2,860.32% 114.38%
2025 -1,334.23% 5,510.72%
2024 -23.78% 38.74%
2023 -17.14% -50.04%
2022 -34.31% -13.82%
2021 -39.81% 1,095.50%
2020 -3.33% -112.17%
2019 27.37% 123.79%
2018 12.23% 37.11%
2017 8.92% 21.69%
2016 7.33% -127.90%
2015 -26.27% 499.77%
2014 -4.38% -86.54%
2013 -32.53% 33.65%
2012 -24.34% -87.59%
2011 -196.13% 404.84%
2010 -38.85% -7.43%
2009 -41.97% -12.94%
2008 -48.21% 0.00%
2007 0.00% -100.00%
2006 -30.76% -56.96%
2005 -71.47% -9,381.82%
2004 0.77% -45.00%
2003 1.40% -27.46%
2002 1.93% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
59.80% -100.02%
US
31.60% -100.01%
SE
30.13% -100.01%
FR
29.76% -100.01%
HK
31.11% -100.01%
IT
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Orexo AB's operating margin

What is Orexo AB's operating margin?

Orexo AB's operating margin is -2,860.32%, as of Nov 2026.

What was Orexo AB's operating margin in 2025?

In 2025, Orexo AB's operating margin was -1,334.23%, compared with -23.78% in 2024.

How has Orexo AB's operating margin changed since 2020?

From 2020 to 2025, Orexo AB's operating margin was highest in 2020 (-3.33%) and lowest in 2025 (-1,334.23%).

How does Orexo AB's operating margin compare with similar companies?

Orexo AB's operating margin (-2,860.32%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 59.80%.